金融界消息 截至2025年8月14日收盘，诚意药业（603811）报收于15.18元，下跌1.81%，换手率 9.07%，成交量29.67万手，成交金额4.58亿元。 资金流向方面，今日主力资金净流出3363.08万元，占比成交额7.34%。其中，超大单净流出2756.35万 元、占成交额6.02%，大单净流出606.73万元、占成交额1.33%，中单净流出流入2054.31万元、占成交 额4.49%，小单净流入1308.77万元、占成交额2.86%。 诚意药业最新一期业绩显示，截至2025一季报，公司营业总收入1.86亿元、同比增长21.26%，归属净利 润4579.32万元，同比增长40.10%，扣非净利润4532.86万元，同比增长46.74%，流动比率1.565、速动比 率1.042、资产负债率22.38%。 天眼查商业履历信息显示，浙江诚意药业股份有限公司，成立于2001年，位于温州市，是一家以从事医 药制造业为主的企业。企业注册资本32730.432万人民币，实缴资本32730.432万人民币。公司法定代表 人为赵春建。 通过天眼查大数据分析，浙江诚意药业股份有限公司共对外投资了8家企业，参与招投 ...

Group 1 - The stock price of Chengyi Pharmaceutical is reported at 15.65 yuan as of August 12, 2025, reflecting a decrease of 0.33 yuan from the previous trading day [1] - The opening price for the day was 16.16 yuan, with a highest point of 16.45 yuan and a lowest point of 15.26 yuan, resulting in an intraday volatility of 7.45% [1] - The trading volume reached 548,445 hands, with a total transaction amount of 870 million yuan [1] Group 2 - Chengyi Pharmaceutical primarily engages in chemical pharmaceutical business, with products covering various therapeutic areas including anti-infection drugs, anti-tumor drugs, and cardiovascular drugs [1] - The company is headquartered in Zhejiang Province and holds a certain market position in the pharmaceutical manufacturing sector [1] Group 3 - On August 12, the net outflow of main funds was 39.1563 million yuan, with a cumulative net outflow of 90.5487 million yuan over the past five trading days [1] - The stock experienced rapid fluctuations during the trading session, with a quick 2% drop at 9:37 AM followed by a 2% rebound at 9:50 AM, indicating active market trading [1]

Group 1 - The first extraordinary general meeting of shareholders for 2025 was held on August 11, 2025, at the company's research and development building in Wenzhou, Zhejiang Province [2] - The meeting was convened by the board of directors and was conducted through a combination of on-site and online voting, presided over by the chairman, Mr. Yan Yiyi [2][3] - All nine current directors attended the meeting, along with the board secretary and some senior executives [3] Group 2 - Three proposals were reviewed and approved during the meeting, including the draft of the 2025 employee stock ownership plan and its management measures [4][5] - The voting results indicated that all proposals received more than half of the valid voting rights, and the meeting ensured separate counting for minority investors [5] - Related shareholders recused themselves from voting on the proposals to maintain compliance with regulations [5] Group 3 - The meeting was witnessed by lawyers from Shanghai Jintiancheng Law Firm, who confirmed that the procedures and voting processes complied with relevant laws and regulations [5]

（文章来源：证券日报） 证券日报网讯 8月11日晚间，诚意药业发布公告称，公司2025年第一次临时股东会于2025年8月11日召 开，审议通过了《关于提请公司股东会授权董事会办理公司2025年员工持股计划相关事宜的议案》等。 ...

Company Overview - Chengyi Pharmaceutical reported a closing price of 15.98 yuan on August 11, down 0.63 yuan, representing a decline of 3.79% from the previous trading day [1] - The stock reached a high of 16.69 yuan and a low of 15.70 yuan during the trading session, with a total trading volume of 563,700 hands and a transaction amount of 900 million yuan [1] Financial Performance - On August 11, the net inflow of main funds was 50.85 million yuan, accounting for 0.97% of the circulating market value [1] - Over the past five trading days, there was a cumulative net outflow of 29.42 million yuan, which is 0.56% of the circulating market value [1] Industry Position - Chengyi Pharmaceutical is focused on the chemical pharmaceutical sector, headquartered in Zhejiang Province [1] - The company's product range includes treatments for infections, cardiovascular diseases, and digestive system disorders, with a research pipeline that features multiple innovative drugs and generic products [1]

上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 2025 年第一次临时股东会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 2025 年第一次临时股东会的 法律意见书 致：浙江诚意药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江诚意药业股份有限 公司（以下简称"公司"）委托，就公司召开 2025 年第一次临时股东会（以下简 称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《上市公司股东会规则》等法律、法规、规章和其他规范性文件以及《浙 江诚意药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本 法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉及的相关事项 进行了 ...

证券代码：603811 证券简称：诚意药业 公告编号：2025-042 浙江诚意药业股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 8 月 11 日 (二)股东会召开的地点：浙江省温州市洞头区化工路 118 号浙江诚意药业股份有 限公司洞头制造部研发大楼会议室 本次股东会由公司董事会召集，以现场和网络投票相结合的方式召开，现场 会议由公司董事长颜贻意先生主持。本次股东会的召集、召开和表决方式符合《公 司法》、《公司章程》等法律法规和规范性文件的规定，所做决议合法有效。 (五)公司董事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、董事会秘书出席本次会议；部分高管列席本次会议。 二、 议案审议情况 (一)非累积投票议案 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 326 | | --- | -- ...

Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. is implementing an employee stock ownership plan (ESOP) to enhance employee motivation and align their interests with shareholders, while ensuring compliance with relevant laws and regulations [1][11]. Group 1: Company Qualifications - Chengyi Pharmaceutical is a legally established and compliant public company, having obtained its business license on May 7, 2013 [3]. - The company has received approval from the China Securities Regulatory Commission for its initial public offering, confirming its legal status [3]. Group 2: Legality and Compliance of the ESOP - The ESOP was approved by the company's board on July 13, 2025, and is designed to last until its expiration or can be extended upon approval [4][8]. - The plan allows for a maximum of 228 participants, including management and key personnel, without any financial assistance from the company [4][5]. - The shares for the ESOP will be sourced from the company's repurchased A-shares, with a total expenditure of approximately RMB 76.4 million at a price of RMB 7.25 per share [5][10]. Group 3: Legal Procedures and Disclosure - The company has conducted necessary legal procedures, including a staff representative meeting and board approvals, in accordance with regulatory requirements [11][12]. - The company has disclosed relevant information regarding the ESOP in compliance with the guidelines set by the China Securities Regulatory Commission [16]. Group 4: Management and Governance - The ESOP will be managed by a committee elected by the participants, ensuring independent operation from the company's controlling shareholders and management [14][15]. - The plan includes provisions for avoiding conflicts of interest and ensuring that participants retain their rights as shareholders [15]. Group 5: Future Steps - The ESOP is pending approval from the shareholders' meeting, which is the final step in the implementation process [13][16].

上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 2025 年员工持股计划的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 2025 年员工持股计划的 法律意见书 致：浙江诚意药业股份有限公司 上海市锦天城律师事务所（以下称"本所"或"锦天城"）接受浙江诚意药业 股份有限公司（以下称"诚意药业"或"公司"）委托，就诚意药业本次拟实施的 2025 年员工持股计划（以下称"本次员工持股计划"）出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》（以下称"《公司法》"）《中华 人民共和国证券法》（以下称"《证券法》"）、中国证券监督管理委员会（以下称 "中国证监会"）发布的《关于上市公司实施员工持股计划试点的指导意见》（以 下称"《指导意见》"）、《上海证券交易所股票上市规则》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》（以下简称"《自律监管指引第 1 号》"） 等有关法律、 ...

龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%、日换手率达20%、日涨幅偏离值 达7%上榜龙虎榜1次，买卖居前营业部中，机构净买入4973.88万元，营业部席位合计净买入6910.65万 元。 诚意药业再度涨停，5个交易日内录得3个涨停，累计涨幅为35.81%，累计换手率为94.58%。截至 13:18，该股今日成交量4709.41万股，成交金额7.48亿元，换手率14.39%。最新A股总市值达54.37亿 元。 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.08.07 | -3.21 | 18.58 | 18.32 | | 2025.08.06 | 5.41 | 29.52 | -7108.85 | | 2025.08.05 | 10.04 | 19.14 | 2746.81 | | 2025.08.04 | 9.98 | 12.95 | 12679.64 | | 2025.08.01 | -3.70 | 9.14 | -1074.10 | | 2025.07.31 | 5.05 | 12. ...